Status:
UNKNOWN
The Progress of Diabetes Mellitus After HMS5552 Treatment in Type 2 Diabetes Mellitus
Lead Sponsor:
Majianhua
Conditions:
Type2 Diabetes Mellitus
Eligibility:
All Genders
18-80 years
Brief Summary
At present, there are few studies on the clinical remission rate of diabetes after one year discontinuation of oral hypoglycemic drugs after intensive treatment. HMS5552 is a kind of GKA hypoglycemic ...
Eligibility Criteria
Inclusion
- Complete HMS5552 treatment and safety visit;
- HbA1c \< 8.0% was detected in our laboratory;
- Researchers judged the stability of glucose control based on the data of subjects'visits during HMS5552 treatment and the indicators of our hospital;
- Subjects are able and willing to monitor peripheral blood sugar and regularity of diet and exercise;
- Willing to sign written informed consent and abide by the research program.
Exclusion
- There was a state of illness in the subjects who could not complete the follow-up during the observation period.
- The researchers judged that subjects'compliance with HMS5552 was affected during treatment.
Key Trial Info
Start Date :
December 12 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2022
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04091854
Start Date
December 12 2018
End Date
March 1 2022
Last Update
August 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanjing First hospital
Nanjing, Jiangsu, China